STA-9090 (ganetespib)

DRUG2 trials

Sponsors

Synta Pharmaceuticals Corp.

Conditions

ALLAMLAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBlast-phase Chronic Myelogenous LeukemiaCMLMDSMyeloproliferative Disorders

Phase 1

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

CompletedNCT00858572

Synta Pharmaceuticals Corp.AML, CML, MDS +1

Start: 2009-03-31End: 2013-02-28Updated: 2014-09-18

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

CompletedNCT00964873

Synta Pharmaceuticals Corp.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, ALL +3

Start: 2009-08-31End: 2011-08-31Updated: 2014-09-18